Comparative Pharmacology
Head-to-head clinical analysis: ISMOTIC versus OSMITROL 5 IN WATER IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISMOTIC versus OSMITROL 5 IN WATER IN PLASTIC CONTAINER.
ISMOTIC vs OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosmotic solution of mannitol; increases plasma osmolality, drawing water from tissues into the vasculature and reducing intracranial/intraocular pressure via osmotic diuresis.
Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal blood flow. It is filtered by glomerulus and not reabsorbed, leading to increased urinary output and reduction of intracranial/intraocular pressure.
1-2 g orally every 6-8 hours, maximum 8 g/day; or 1-2 g intravenously over 5-10 minutes every 6-8 hours, maximum 8 g/day.
Intravenous infusion. Usual adult dose: 50-100 grams (500-1000 mL of 5% solution) administered over 30-60 minutes. Frequency: every 6-12 hours as needed for cerebral edema or reduction of intraocular pressure.
None Documented
None Documented
4.5-6.0 hours in adults with normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria)
The terminal elimination half-life is approximately 1.5 to 2 hours in adults with normal renal function. This can be prolonged to 6-12 hours in patients with renal impairment, requiring dose adjustment.
Renal: 90-95% unchanged; biliary/fecal: <5%
Mannitol is excreted primarily by the kidneys via glomerular filtration, with approximately 80% of an administered dose appearing unchanged in urine within 3 hours. Less than 10% undergoes tubular reabsorption; negligible biliary or fecal elimination (<1%).
Category C
Category C
Osmotic Diuretic
Osmotic Diuretic